Published in J Bone Miner Res on March 29, 2004
Osteoporosis: now and the future. Lancet (2011) 5.81
Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. Lancet (2013) 5.57
European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int (2008) 5.27
Clinician's Guide to Prevention and Treatment of Osteoporosis. Osteoporos Int (2014) 5.17
European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int (2012) 4.88
Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int (2008) 4.73
The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res (2012) 4.15
Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc (2008) 2.66
Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study. Osteoporos Int (2006) 2.34
American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis. Endocr Pract (2011) 2.29
Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study. Osteoporos Int (2015) 2.15
Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report. Osteoporos Int (2010) 1.83
Performance of the Osteoporosis Self-Assessment Tool in ruling out low bone mineral density in postmenopausal women: a systematic review. Osteoporos Int (2007) 1.80
Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data. Osteoporos Int (2008) 1.76
Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis (2005) 1.66
Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int (2008) 1.65
Persistence with weekly alendronate therapy among postmenopausal women. Osteoporos Int (2006) 1.56
Absolute risk reduction in osteoporosis: assessing treatment efficacy by number needed to treat. Rheumatol Int (2009) 1.53
The role of DXA bone density scans in the diagnosis and treatment of osteoporosis. Postgrad Med J (2007) 1.51
Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis. Calcif Tissue Int (2011) 1.50
Biochemical markers of bone turnover: potential use in the investigation and management of postmenopausal osteoporosis. Osteoporos Int (2008) 1.50
Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res (2016) 1.50
New targets for intervention in the treatment of postmenopausal osteoporosis. Nat Rev Rheumatol (2011) 1.43
Effect of daily oral minodronate on vertebral fractures in Japanese postmenopausal women with established osteoporosis: a randomized placebo-controlled double-blind study. Osteoporos Int (2008) 1.42
Effect of dosing interval duration of intermittent ibandronate treatment on the healing process of femoral osteotomy in a rat fracture model. Calcif Tissue Int (2012) 1.41
UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos (2017) 1.40
Adverse effects of bisphosphonates: implications for osteoporosis management. Mayo Clin Proc (2009) 1.39
The assessment of fracture risk. J Bone Joint Surg Am (2010) 1.27
Bone mass is preserved and cancellous architecture altered due to cyclic loading of the mouse tibia after orchidectomy. J Bone Miner Res (2008) 1.25
Does a history of non-vertebral fracture identify women without osteoporosis for treatment? J Gen Intern Med (2008) 1.23
Bisphosphonates in the management of postmenopausal osteoporosis--optimizing efficacy in clinical practice. Clin Interv Aging (2008) 1.22
Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial. J Clin Endocrinol Metab (2014) 1.20
Theoretical implications of the biomechanical fracture threshold. J Bone Miner Res (2008) 1.16
Individualizing osteoporosis therapy. Osteoporos Int (2012) 1.15
Interventions to improve adherence and persistence with osteoporosis medications: a systematic literature review. Osteoporos Int (2009) 1.14
Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis. Rheumatol Int (2009) 1.14
Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study. Osteoporos Int (2011) 1.13
Prevention of osteoporosis-related fractures among postmenopausal women and older men. CMAJ (2009) 1.12
Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis. Ther Clin Risk Manag (2010) 1.12
Prevention and treatment of postmenopausal osteoporosis. J Steroid Biochem Mol Biol (2013) 1.10
Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies. Osteoporos Int (2005) 1.09
The Osteoporosis Self-Assessment Tool versus alternative tests for selecting postmenopausal women for bone mineral density assessment: a comparative systematic review of accuracy. Osteoporos Int (2008) 1.05
Clinical efficacy on fracture risk and safety of 0.5 mg or 1 mg/month intravenous ibandronate versus 2.5 mg/day oral risedronate in patients with primary osteoporosis. Calcif Tissue Int (2013) 1.05
Antiresorptive therapies for osteoporosis: a clinical overview. Nat Rev Endocrinol (2011) 1.04
Effective and rapid treatment of painful localized transient osteoporosis (bone marrow edema) with intravenous ibandronate. Osteoporos Int (2005) 1.03
Aging and bone loss: new insights for the clinician. Ther Adv Musculoskelet Dis (2012) 1.02
Salmon calcitonin: a review of current and future therapeutic indications. Osteoporos Int (2007) 1.02
Lack of association between oral bisphosphonates and osteonecrosis using jaw surgery as a surrogate marker. Osteoporos Int (2008) 0.99
Vertebral morphometry: current methods and recent advances. Eur Radiol (2008) 0.99
The relative efficacy of nine osteoporosis medications for reducing the rate of fractures in post-menopausal women. BMC Musculoskelet Disord (2011) 0.99
National Bone Health Alliance Bone Turnover Marker Project: current practices and the need for US harmonization, standardization, and common reference ranges. Osteoporos Int (2012) 0.99
The association between compliance and persistence with bisphosphonate therapy and fracture risk: a review. BMC Musculoskelet Disord (2007) 0.99
Femoral neck cortical geometry measured with magnetic resonance imaging is associated with proximal femur strength. Osteoporos Int (2006) 0.99
Vitamin D and ibandronate prevent cancellous bone loss associated with binge alcohol treatment in male rats. Bone (2007) 0.98
Bisphosphonates and osteoporotic fractures: a cross-design synthesis of results among compliant/persistent postmenopausal women in clinical practice versus randomized controlled trials. Osteoporos Int (2009) 0.97
Monthly oral ibandronate is effective and well tolerated after 3 years: the MOBILE long-term extension. Clin Rheumatol (2008) 0.97
Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club. Osteoporos Int (2010) 0.97
A list of device-specific thresholds for the clinical interpretation of peripheral x-ray absorptiometry examinations. Osteoporos Int (2005) 0.96
Which Bisphosphonate? It's the Compliance!: Decision Analysis. J Bone Metab (2016) 0.96
Using computers to identify non-compliant people at increased risk of osteoporotic fractures in general practice: a cross-sectional study. Osteoporos Int (2006) 0.95
Osteoporotic fractures in older adults. Best Pract Res Clin Rheumatol (2006) 0.95
Efficacy of monthly oral ibandronate is sustained over 5 years: the MOBILE long-term extension study. Osteoporos Int (2011) 0.95
Martial arts fall training to prevent hip fractures in the elderly. Osteoporos Int (2009) 0.94
Bisphosphonate drug holiday: choosing appropriate candidates. Curr Osteoporos Rep (2013) 0.93
Patient preference in the management of postmenopausal osteoporosis with bisphosphonates. Clin Interv Aging (2006) 0.93
Safety and tolerability of zoledronic acid and other bisphosphonates in osteoporosis management. Drug Healthc Patient Saf (2010) 0.92
Assessment of non-vertebral fracture risk in postmenopausal women. Ann Rheum Dis (2007) 0.92
Current, new and future treatments of osteoporosis. Rheumatol Int (2010) 0.92
Validation of diagnostic codes for subtrochanteric, diaphyseal, and atypical femoral fractures using administrative claims data. J Clin Densitom (2011) 0.91
Effect of once-yearly zoledronic acid five milligrams on fracture risk and change in femoral neck bone mineral density. J Clin Endocrinol Metab (2009) 0.91
Hospitalisations for fracture and associated costs between 2000 and 2009 in Ireland: a trend analysis. Osteoporos Int (2012) 0.90
Long-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis: 5-year data from the DIVA study long-term extension. Osteoporos Int (2012) 0.90
Targeted approaches in the treatment of osteoporosis: differential mechanism of action of denosumab and clinical utility. Ther Clin Risk Manag (2012) 0.90
Treatment of postmenopausal osteoporosis. BMJ (2005) 0.90
Intravenous bisphosphonates for postmenopausal osteoporosis. J Res Med Sci (2010) 0.90
Diagnosis and management of osteoporosis in the older senior. Clin Interv Aging (2009) 0.90
What is the best balance of benefits and risks among anti-resorptive therapies for postmenopausal osteoporosis? Osteoporos Int (2010) 0.89
Management of osteoporosis among home health and long-term care patients with a prior fracture. South Med J (2009) 0.89
Adherence and occurrence of fractures after switching to once-monthly oral bisphophonates. Pharmacoepidemiol Drug Saf (2010) 0.88
Comparison of monthly ibandronate versus weekly risedronate in preference, convenience, and bone turnover markers in Korean postmenopausal osteoporotic women. Calcif Tissue Int (2009) 0.88
Long-term fracture rates seen with continued ibandronate treatment: pooled analysis of DIVA and MOBILE long-term extension studies. Osteoporos Int (2013) 0.88
American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis: executive summary of recommendations. Endocr Pract (2011) 0.88
Mammalian hibernation as a model of disuse osteoporosis: the effects of physical inactivity on bone metabolism, structure, and strength. Am J Physiol Regul Integr Comp Physiol (2008) 0.88
Longitudinal change in clinical fracture incidence after initiation of bisphosphonates. Osteoporos Int (2009) 0.87
Osteoporosis medication profile preference: results from the PREFER-US study. Health Expect (2007) 0.87
Comparing non-vertebral fracture risk reduction with osteoporosis therapies: looking beneath the surface. Osteoporos Int (2008) 0.87
Management of osteoporosis of the oldest old. Osteoporos Int (2014) 0.87
Time to onset of efficacy in fracture reduction with current anti-osteoporosis treatments. J Bone Miner Metab (2012) 0.86
Oral bisphosphonates may not decrease hip fracture risk in elderly Spanish women: a nested case-control study. BMJ Open (2013) 0.86
Progress in osteoporosis and fracture prevention: focus on postmenopausal women. Arthritis Res Ther (2009) 0.85
Clinical role of bisphosphonate therapy. Int J Womens Health (2012) 0.85
Epidemiology and management of osteoporosis in the People's Republic of China: current perspectives. Clin Interv Aging (2015) 0.84
Fracture prevention in postmenopausal women. BMJ Clin Evid (2011) 0.84
Treatment of primary osteoporosis in men. Clin Interv Aging (2014) 0.84
Reducing hip fracture risk with risedronate in elderly women with established osteoporosis. Clin Interv Aging (2009) 0.84
Adoption of once-monthly oral bisphosphonates and the impact on adherence. Am J Med (2010) 0.84
Increased bone mineral density with monthly intravenous ibandronate contributes to fracture risk reduction in patients with primary osteoporosis: three-year analysis of the MOVER study. Calcif Tissue Int (2014) 0.83
Bisphosphonates for the prevention and treatment of osteoporosis in patients with rheumatic diseases: a systematic review and meta-analysis. PLoS One (2013) 0.83
Evidence-based guidelines for the treatment of postmenopausal osteoporosis: a consensus document of the Belgian Bone Club. Osteoporos Int (2005) 0.83
Management of age-related osteoporosis and prevention of associated fractures. Ther Clin Risk Manag (2006) 0.83
Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet (2006) 19.03
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med (2007) 18.27
Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med (2009) 13.57
A variant in CDKAL1 influences insulin response and risk of type 2 diabetes. Nat Genet (2007) 13.28
Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat Genet (2007) 12.65
Bone quality--the material and structural basis of bone strength and fragility. N Engl J Med (2006) 7.45
Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res (2007) 6.76
Multiple genetic loci for bone mineral density and fractures. N Engl J Med (2008) 6.35
Refining the impact of TCF7L2 gene variants on type 2 diabetes and adaptive evolution. Nat Genet (2007) 5.88
Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med (2002) 5.83
Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med (2010) 5.60
Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat Genet (2012) 5.48
In vivo assessment of trabecular bone microarchitecture by high-resolution peripheral quantitative computed tomography. J Clin Endocrinol Metab (2005) 5.31
Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind, randomised placebo-controlled trial. Ann Rheum Dis (2012) 4.81
The effects of tibolone in older postmenopausal women. N Engl J Med (2008) 3.96
New sequence variants associated with bone mineral density. Nat Genet (2008) 3.43
Peripheral adiposity exhibits an independent dominant antiatherogenic effect in elderly women. Circulation (2003) 3.37
Finite element analysis based on in vivo HR-pQCT images of the distal radius is associated with wrist fracture in postmenopausal women. J Bone Miner Res (2008) 3.33
Alterations of cortical and trabecular architecture are associated with fractures in postmenopausal women, partially independent of decreased BMD measured by DXA: the OFELY study. J Bone Miner Res (2007) 3.31
Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum (2006) 2.82
Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial. J Am Dent Assoc (2008) 2.75
Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res (2015) 2.74
Prevention of postmenopausal bone loss by a low-magnitude, high-frequency mechanical stimuli: a clinical trial assessing compliance, efficacy, and safety. J Bone Miner Res (2003) 2.72
Uncoupling of type II collagen synthesis and degradation predicts progression of joint damage in patients with knee osteoarthritis. Arthritis Rheum (2002) 2.66
Genome-wide association study identifies sequence variants on 6q21 associated with age at menarche. Nat Genet (2009) 2.58
Nonsense mutation in the LGR4 gene is associated with several human diseases and other traits. Nature (2013) 2.55
Relationship between osteoporosis and cardiovascular disease in postmenopausal women. J Bone Miner Res (2005) 2.49
Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate. J Bone Miner Res (2010) 2.37
Genome-wide association study using extreme truncate selection identifies novel genes affecting bone mineral density and fracture risk. PLoS Genet (2011) 2.34
Enlarged waist combined with elevated triglycerides is a strong predictor of accelerated atherogenesis and related cardiovascular mortality in postmenopausal women. Circulation (2005) 2.30
The effect of oral calcitonin on cartilage turnover and surface erosion in an ovariectomized rat model. Arthritis Rheum (2007) 2.22
Clinical use of quantitative computed tomography and peripheral quantitative computed tomography in the management of osteoporosis in adults: the 2007 ISCD Official Positions. J Clin Densitom (2008) 2.21
Common variants at VRK2 and TCF4 conferring risk of schizophrenia. Hum Mol Genet (2011) 2.21
Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate: review of statistical analysis. J Bone Miner Res (2007) 2.15
Calcium and vitamin d supplementation decreases incidence of stress fractures in female navy recruits. J Bone Miner Res (2008) 2.06
Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. J Bone Miner Res (2008) 2.04
Bone fragility: failure of periosteal apposition to compensate for increased endocortical resorption in postmenopausal women. J Bone Miner Res (2006) 2.04
Association of five quantitative ultrasound devices and bone densitometry with osteoporotic vertebral fractures in a population-based sample: the OPUS Study. J Bone Miner Res (2004) 2.01
Microcrack frequency and bone remodeling in postmenopausal osteoporotic women on long-term bisphosphonates: a bone biopsy study. J Bone Miner Res (2007) 1.97
Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. Bone (2007) 1.97
Hormonal and lifestyle determinants of appendicular skeletal muscle mass in men: the MINOS study. Am J Clin Nutr (2004) 1.96
Biological markers in osteoarthritis. Nat Clin Pract Rheumatol (2007) 1.95
Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures. J Bone Miner Res (2012) 1.92
Establishing a reference interval for bone turnover markers in 637 healthy, young, premenopausal women from the United Kingdom, France, Belgium, and the United States. J Bone Miner Res (2009) 1.89
Bone loss is detected more frequently in patients with ankylosing spondylitis with syndesmophytes. J Rheumatol (2005) 1.84
Are nonresorbing osteoclasts sources of bone anabolic activity? J Bone Miner Res (2007) 1.82
Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res (2005) 1.81
Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res (2008) 1.79
Early postmenopausal hormone therapy may prevent cognitive impairment later in life. Menopause (2005) 1.77
Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res (2004) 1.76
Segmenting articular cartilage automatically using a voxel classification approach. IEEE Trans Med Imaging (2007) 1.73
Sequence variants in the CLDN14 gene associate with kidney stones and bone mineral density. Nat Genet (2009) 1.73
Suppression of elevated cartilage turnover in postmenopausal women and in ovariectomized rats by estrogen and a selective estrogen-receptor modulator (SERM). Menopause (2004) 1.66
Muscle atrophy and bone loss after 90 days' bed rest and the effects of flywheel resistive exercise and pamidronate: results from the LTBR study. Bone (2005) 1.65
Risedronate prevents new vertebral fractures in postmenopausal women at high risk. J Clin Endocrinol Metab (2003) 1.65
Linkage of osteoporosis to chromosome 20p12 and association to BMP2. PLoS Biol (2003) 1.64
Efficacy and safety of oral strontium ranelate for the treatment of knee osteoarthritis: rationale and design of randomised, double-blind, placebo-controlled trial. Curr Med Res Opin (2012) 1.64
Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis. J Bone Miner Res (2006) 1.58
Identification of osteopenic women at high risk of fracture: the OFELY study. J Bone Miner Res (2005) 1.56
A meta-analysis of the association of fracture risk and body mass index in women. J Bone Miner Res (2014) 1.56
Long-term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum (2009) 1.54
Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. J Clin Endocrinol Metab (2008) 1.53
Role of gastrointestinal hormones in postprandial reduction of bone resorption. J Bone Miner Res (2003) 1.52
Finite element analysis performed on radius and tibia HR-pQCT images and fragility fractures at all sites in postmenopausal women. Bone (2010) 1.52
Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a five-year, randomized, placebo-controlled trial. Arthritis Rheum (2008) 1.51
The effect of hydroxyethyl starches (HES 130/0.42 and HES 200/0.5) on activated renal tubular epithelial cells. Anesth Analg (2009) 1.51
Histomorphometric and microCT analysis of bone biopsies from postmenopausal osteoporotic women treated with strontium ranelate. J Bone Miner Res (2008) 1.51
Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis. Calcif Tissue Int (2011) 1.50
Severity of vertebral fractures is associated with alterations of cortical architecture in postmenopausal women. J Bone Miner Res (2009) 1.49
An update on the antiestrogenic effect of smoking: a literature review with implications for researchers and practitioners. Menopause (2004) 1.49
Clinical evaluation of medicinal products for acceleration of fracture healing in patients with osteoporosis. Bone (2008) 1.48
Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Bone (2008) 1.44
Cartilage degradation is fully reversible in the presence of aggrecanase but not matrix metalloproteinase activity. Arthritis Res Ther (2008) 1.43
Estimated number of women likely to benefit from bone mineral density measurement in France. Joint Bone Spine (2004) 1.41
Alveolar macrophages regulate neutrophil recruitment in endotoxin-induced lung injury. Respir Res (2005) 1.40
Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: reduction in risk of nonvertebral fracture is not related to change in BMD. J Bone Miner Res (2005) 1.39
Acute changes in neuromuscular excitability after exhaustive whole body vibration exercise as compared to exhaustion by squatting exercise. Clin Physiol Funct Imaging (2003) 1.39
The disease modifying osteoarthritis drug (DMOAD): Is it in the horizon? Pharmacol Res (2008) 1.38
Non-enzymatic glycation of bone collagen modifies osteoclastic activity and differentiation. J Biol Chem (2006) 1.36
Vascular adaptation to deconditioning and the effect of an exercise countermeasure: results of the Berlin Bed Rest study. J Appl Physiol (1985) (2005) 1.36
Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study. J Bone Miner Res (2008) 1.32
Bone material properties in trabecular bone from human iliac crest biopsies after 3- and 5-year treatment with risedronate. J Bone Miner Res (2006) 1.32
Effects of denosumab on bone turnover markers in postmenopausal osteoporosis. J Bone Miner Res (2011) 1.32
Comprehensive association analysis of nine candidate genes with serum 25-hydroxy vitamin D levels among healthy Caucasian subjects. Hum Genet (2010) 1.31
Identification of progressors in osteoarthritis by combining biochemical and MRI-based markers. Arthritis Res Ther (2009) 1.30
Extracellular matrix remodeling: the common denominator in connective tissue diseases. Possibilities for evaluation and current understanding of the matrix as more than a passive architecture, but a key player in tissue failure. Assay Drug Dev Technol (2012) 1.30
Contribution of trochanteric soft tissues to fall force estimates, the factor of risk, and prediction of hip fracture risk. J Bone Miner Res (2007) 1.29
Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn's disease. Clin Gastroenterol Hepatol (2005) 1.29
Is muscle power output a key factor in the age-related decline in physical performance? A comparison of muscle cross section, chair-rising test and jumping power. Clin Physiol Funct Imaging (2004) 1.28
Finite element analysis performed on radius and tibia HR-pQCT images and fragility fractures at all sites in men. J Bone Miner Res (2011) 1.28